Comparison · NCT00910429-deaths
Former Riociguat 1.0-2.5 mg vs Former Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Former Riociguat 1.0-2.5 mg vs Former Placebo: deaths from any cause. Trial comparisons, record NCT00910429-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00910429-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.142 | 0.0956 | 0.206 | wilson | |
| Risk in group 2 | 0.159 | 0.0951 | 0.253 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0166 | -0.121 | 0.0733 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.895 | 0.476 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 0.878 | 0.417 | 1.85 | log | |
| Number needed to treat, for one fewer death from any cause on Former Riociguat 1.0-2.5 mg than on Former Placebo | 60.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Former Riociguat 1.0-2.5 mg | Subjects from the riociguat 1.0-2.5 mg group of CHEST-1 entered the extension study(CHEST-2) with the same dose as they received on the last day of CHEST-1 (Visit7). | 22 | 155 | EG000 |
| Group 2 | Former Placebo | Subjects from the placebo group of CHEST-1 entered the extension study (CHEST-2),the starting dose in CHEST-2 was 1.0 mg riociguat tid. | 13 | 82 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years.
Source ClinicalTrials.gov
Trial
- Title
- BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
- NCT number
- NCT00910429
- Phases
- PHASE3
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521)
- Lead sponsor
- Bayer
- Results first posted
- 2020-10-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00910429?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00910429-deaths